Disc Medicine (IRON) Total Non-Current Liabilities (2020 - 2023)
Disc Medicine (IRON) posted quarterly Total Non-Current Liabilities of $16.0 million for Q3 2023, up 994.47% year-over-year from $1.5 million in Q3 2022, and up 39.88% quarter-over-quarter from $11.5 million in Q2 2023.
Powered by 
Analysis
Disc Medicine (IRON) Total Non-Current Liabilities (2020 - 2023) Analysis & Trends
Disc Medicine (IRON) has reported Total Non-Current Liabilities for 4 consecutive years, with $16.0 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Total Non-Current Liabilities rose 994.47% year-over-year to $16.0 million; the TTM figure through Sep 2023 stood at $16.0 million (up 994.47% YoY), while the FY2022 annual figure was $23.6 million, up 184.12% from the prior year.
- Total Non-Current Liabilities advanced to $16.0 million in Q3 2023 per IRON's latest filing, from $11.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $29.9 million in Q4 2020 and bottomed at -$66000.0 in Q1 2020.
- Historically, Total Non-Current Liabilities has averaged $12.0 million across 4 years, with a median of $12.7 million in 2022.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 27228.79% — and 2022, when it slumped 89.77%.
- Disc Medicine's Total Non-Current Liabilities stood at $29.9 million in 2020, then sank by 72.22% to $8.3 million in 2021, then jumped by 184.12% to $23.6 million in 2022, then plunged by 32.12% to $16.0 million in 2023.
- Business Quant data shows IRON's Total Non-Current Liabilities at $16.0 million in Q3 2023, $11.5 million in Q2 2023, and $23.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 16.02 Mn |
| Jun 30, 2023 | 11.46 Mn |
| Dec 31, 2022 | 23.61 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 6.44 Mn |
| Mar 31, 2022 | 12.67 Mn |
| Dec 31, 2021 | 14.40 Mn |
| Sep 30, 2021 | 14.31 Mn |
| Jun 30, 2021 | 14.39 Mn |
| Mar 31, 2021 | 17.91 Mn |
| Dec 31, 2020 | 29.90 Mn |
| Jun 30, 2020 | 6.55 Mn |
| Mar 31, 2020 | -76,000.00 |